Search Results for: BIIB
Biogen-Iden (NASDAQ:BIIB) is seeing its shares pummeled in after-hours trading. The company didn’t have another biotech drug crisis though. Biogen had been under a corporate strategic...
Published:
Last Updated:
The research calls are running light as many markets either close early or are on very low volume with skeleton crews manning the trading desks. These are some of this Friday’s key analyst...
Published:
Last Updated:
Biogen Idec inc. (BIIB-NASDAQ) is trading up roughly 4% pre-market at $51.40, within striking distance of its $52.72 high over the last year on news of a share buyback plan. That is also the...
Published:
Genentech, Inc. (NYSE:DNA) and Biogen Idec, Inc. (Nasdaq:BIIB) came out this morning with some disappointing news. The biotech giants have announced that a Phase II/III study of Rituxan for...
Published:
Elan Corporation, plc (NYSE: ELN) may be surging on news that it is going to spin off its drug research unit, but now there is something else to consider. Elan could be getting closer and closer...
Published:
Last Updated:
Elan Corporation (ELN) Problems with one of the company’s major drugs. Falls to $9.55 from 52-week high of $37.45.Gatehouse (GHS) More poor newspaper earnings raise issue of whether company is...
Published:
Last Updated:
Icahn Enterprises LP (NYSE: IEP) is perhaps known more for its billionaire owner/founder Carl Icahn more than it is for its staff, team efforts, and even the enterprise’s name. Icahn’s...
Published:
Last Updated:
Biogen Idec Inc. (NASDAQ: BIIB) just came out with an SEC filing showing that on December 11, 2008, regulatory agencies were notified of a confirmed case of progressive multifocal...
Published:
Last Updated:
Biotech is the land of promise for emerging players. It is also the land of stagnation for well established and sturdy giants. Amgen, Inc. (NASDAQ: AMGN), Biogen Idec Inc. (NASDAQ: BIIB), and...
Published:
Last Updated:
Carl Icahn has evolved over the years, first rising to fame a "corporate raider", followed by an ill-fated journey into actual management at the helm of TWA and, most recently, as a kinder, gentler...
Published:
Last Updated:
There was interesting event in a 13D filing today right after the close, and that will be worth some news and gossip alike. An investment firm called Amalgamated Gadget LP, which is roughly a...
Published:
Last Updated:
Biogen Idec (NASDAQ: BIIB) is sliding marginally despite reported earnings today that showed a 23% increase in earnings riding on sales growth on Avonex and Rituxan. The earnings beat estimates and...
Published:
Thursday after the close, we’ll get to see earnings out of Genentech (NASDAQ: DNA). The estimates from First Call are $0.82 EPS on $3.11 billion in revenues. Next quarter estimates are $0.86...
Published:
We have compiled several options chains we are watching today now that the DEC-2009 PUTS/CALLS have expired on Friday. Much of this likely options roll-outs continuing, but we are seeing some...
Published:
Last Updated:
Here are some of the top stories affecting key drug and biotech stocks that have links through to more in-depth coverage and analysis today at the website BioHealthInvestor.com: Rigel Pharmaceuticals...
Published: